Serum lidocaine levels following administration of topical lidocaine during in office laryngopharyngeal procedures

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12616000058471

Acronym

nil

Enrollment

Registered

2016-01-20

Start date

2018-11-19

Completion date

2021-12-31

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

In office laryngeal procedures are well tolerated by most patients provided adequate local anaesthesia is achieved. For most laryngologists topical lidocaine is the agent of choice and is considered safe when used in low doses. However the effects of lidocaine toxicity are well known. This study will evaluate and measure the exact serum levels of lidocaine achieved by topical application of lidocaine for in-office procedures in 50 consecutive patients. Analysis will compare real measured levels to reported safe serum levels and correlate this with side effects if present.

Interventions

Sampling blood for estimation of lidocaine levels after topical administration of lidocaine during awake laryngopharyngeal procedures (sampled prior to, 5,10,20, 30 and 60 minutes following administration). Currently the reported range of administered lidocaine is from 220mg to 1200mg. At our institution the average administered dose topically is 340mg.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients undergoing awake laryngopharyngeal procedures in the office requiring topical anaesthesia Age >18 years Ability to give informed consent

Exclusion criteria

Age <18 yrs Preexisting increased risk of bleeding or thrombosis Coagulation disorders Renal disease Hepatic disease Pre-exisiting cardiac conduction abnormality Inability to provide informed consent Allergy to lidocaine

Outcome results